Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lexeo Therapeutics Q3 2026 Results: Net Loss of $38.3M, Loss Widens

Lexeo Therapeutics reported total assets of $243.9 million as of September 30, 2026, a decrease from $268.7 million at year-end 2025. The company maintains a strong liquidity position with $90.2 million in cash and cash equivalents and $104.6 million in current U.S. Treasury securities to fund its ongoing clinical development of LX2006 and LX2020.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-38.3-20.3
Net income-38.3-20.3
EPS (diluted, $ a share)$-0.43$-0.33

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: LXEO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lexeo Therapeutics, Inc.: key numbers

Share price
$3.23Close, Nov 16
Market cap
$267M
Shares outstanding
82.79MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lexeo Therapeutics, Inc.

All →
7:03 AM ET 8-K
Clinical Trial Data

Lexeo Therapeutics Clinical Trial Data

Lexeo Therapeutics announced positive interim Phase I/II data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, showing an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) in high-dose cohorts. The company also reported that the FDA is open to using NSVT as a primary surrogate endpoint to support potential accelerated approval in a planned pivotal study.

“The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM.”

R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics
4:21 PM ET 8-K
M&A Deal

Lexeo Therapeutics Signs $8.3M M&A Deal with Mantle Therapeutics Inc.

Lexeo Therapeutics completed its acquisition of Mantle Therapeutics for an upfront consideration of $5.3 million in cash and $3.0 million in common stock. The deal includes contingent payments of up to $13.0 million, consisting of a $1.0 million cash payment and $12.0 million in development and regulatory milestones over a 12-year term.

Value
$8.3M
Counterparty
Mantle Therapeutics Inc.
Term
12 years
7:09 AM ET 8-K
M&A Deal

Lexeo Therapeutics Signs $8.3M M&A Deal with Mantle Therapeutics Inc.

Lexeo Therapeutics entered into a definitive agreement to acquire Mantle Therapeutics for an upfront purchase price of $5.3 million in cash and $3.0 million in common stock. The deal includes up to $12.0 million in contingent development and regulatory milestone payments plus a $1.0 million cash payment upon specific events, aimed at expanding Lexeo's Friedreich ataxia (FA) pipeline with new CNS-targeted modalities.

Value
$8.3M
Counterparty
Mantle Therapeutics Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.